Meeting
2017 ASCO Annual Meeting
Humanistic burden of disease in earlier stage metastatic (stage IIIb/c-IVM1a) versus late stage metastatic (IVM1b/c) melanoma patients in a real-world setting in the U.S.
Authors
Jacqueline Buchanan
Amgen, San Francisco, CA
Jacqueline Buchanan , Swaminathan Murugappan , Rebecca Moon , Adam Roughley , Alex Rider
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9561)
DOI
10.1200/JCO.2017.35.15_suppl.9561
Abstract #
9561
Poster Bd #
169
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2022 ASCO Annual Meeting
Progression and mortality post-immunotherapy discontinuation among patients with BRAFV600-mutant (BRAF+) metastatic melanoma.
First Author: Sunandana Chandra
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648.
First Author: John A. Bridgewater
Poster
2021 ASCO Annual Meeting
Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.
First Author: Jeffrey S. Weber